Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation-positive NSCLC: An interim analysis of the ARIA study

被引：0
|
作者：
Wu, L. [1 ,2 ]
Li, J. [3 ]
Xu, C. [4 ,5 ]
Biswas, B. [6 ]
Tang, K. [7 ]
Wang, H. [8 ,9 ]
Liu, Z. [10 ]
Batra, U. [11 ]
Ho, G. F. [12 ]
Low, S. H. J. [13 ]
Lu, Y. [14 ]
Zhao, M. [15 ]
Tho, L. M. [16 ]
Zhao, J. [17 ]
He, S. [18 ]
Huang, J. [19 ]
Tang, X. [20 ]
Wong, C. H. [21 ]
Wu, Y-L. [4 ,5 ]
机构：
[1] Cent South Univ, Dept Med Oncol, Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, China Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[4] Guangdong Prov Peoples Hosp, Lung Canc Inst, Guangzhou, Peoples R China
[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India
[7] Sun Yat Sen Univ, Resp & Crit Care Med Dept, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] First Hosp Jilin Univ, Dept Oncol Ctr, Changchun, Peoples R China
[11] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India
[12] Univ Malaya, Dept Clin Oncol, Med Ctr, Kuala Lumpur, Malaysia
[13] Pantai Hosp, Oncol & Radiotherapy, Kuala Lumpur, Malaysia
[14] Sichuan Univ, West China Sch Clin Med, West China Hosp, Oncol, Chengdu, Peoples R China
[15] China Med Univ, Dept Oncol, Hosp 1, Shenyang, Peoples R China
[16] Beacon Hosp, Dept Clin Oncol, Petaling Jaya, Malaysia
[17] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol, Minist Educ, Beijing, Peoples R China
[18] Pfizer Inc, Clin Dev, Shanghai, Peoples R China
[19] Pfizer China Res & Dev Co Ltd, Clin Data Qual Dev China, Shanghai, Peoples R China
[20] Pfizer Inc, Pfizer GB & DM, CHN Stat, Shanghai, Peoples R China
[21] Pfizer Pte Ltd, Med Affairs, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1337P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
    Riely, G.
    Lovly, C.
    Messina, C.
    Bienert, S.
    Alexander, K.
    Pao, W.
    Magee, K.
    Baxi, S.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S365 - S366
  • [42] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [43] Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients.
    Zhao, Wei
    Liu, Xingchen
    Tian, Qing
    Chang, Yan
    Yang, Zhen
    Chen, Liangan
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (04): : 1917 - 1921
  • [44] Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib
    Yao, Zong-Han
    Liao, Wei-Yu
    Ho, Chao-Chi
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Chen, Jin-Shing
    Lin, Zhong-Zhe
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    ONCOLOGIST, 2017, 22 (09): : 1075 - 1083
  • [45] Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross A.
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    LUNG CANCER, 2019, 127 : 103 - 111
  • [46] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
  • [47] Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma a real-world retrospective study
    Batra, Ullas
    Sharma, Mansi
    Jain, Parveen
    Narayan, Satya
    Jain, Arpit
    Soni, Satyajeet
    Nathany, Shrinidhi
    INDIAN JOURNAL OF CANCER, 2024, 61 (04) : 671 - 675
  • [48] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [49] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
  • [50] Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm
    Nieva, J.
    Chapaneri, J.
    Lau, Y. K.
    Cooper, M.
    Karia, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S191
12345